Biopharma & Life Sciences
Royalty Pharma Executive Compensation (FY25)
RPRX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Pablo Legorreta | Latest say-on-pay support = June 4, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Royalty Pharma brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 27, 2026Latest filing (8-K): June 4, 2026
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
112 figures on this page: 106 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Say-on-pay support: 91.6% → 97.7% (6.1 points higher)
CEO pay ratio: 240:1 → 4:1 (98.3% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Royalty Pharma's chief executive and what were they paid?
Pablo Legorreta was paid $937,500 in total compensation as Chairman and Chief Executive Officer for fiscal 2025.
What was Royalty Pharma's say-on-pay result?
Shareholders supported the say-on-pay proposal with 97.7% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Royalty Pharma's peer group?
Companies named in the disclosed peer group include AbbVie, Amgen, Apollo, Ares and Biogen, among others. Companies named in the Biopharmaceutical Peer Group include AbbVie, Amgen, Biogen, BioMarin and Bristol-Myers Squibb, among others. The Capital Allocator Peer Group names Apollo, Ares, Blackstone, Carlyle and KKR, among others.
What is Royalty Pharma's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 4:1, against median employee compensation of $349,893.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Marshall Urist Executive Vice President, Research & Investments | ◇ | ◇ | — | — | — | — | — | ◇ |
George Lloyd Executive Vice President, Investments & Chief Legal Officer | ◇ | ◇ | — | — | — | — | — | ◇ |
Christopher Hite Executive Vice President & Vice Chairman | ◇ | ◇ | — | — | — | — | — | ◇ |
Terrance Coyne Executive Vice President & Chief Financial Officer | ◇ | ◇ | — | — | — | — | — | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Marshall Urist Executive Vice President, Research & Investments | ◇ | ◇ | — | — | — | — | — | ◇ |
George Lloyd Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | ◇ | ◇ | — | — | — | — | — | ◇ |
Terrance Coyne Executive Vice President & Chief Financial Officer | ◇ | ◇ | — | — | — | — | — | ◇ |
Christopher Hite Executive Vice President & Vice Chairman | ◇ | ◇ | — | — | — | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Christopher Hite Executive Vice President & Vice Chairman | ◇ | — | — | — | — | — | — | ◇ |
George Lloyd Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | ◇ | — | — | — | — | — | — | ◇ |
Terrance Coyne Executive Vice President & Chief Financial Officer | ◇ | — | — | — | — | — | — | ◇ |
Marshall Urist Executive Vice President, Research & Investments | ◇ | — | — | — | — | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Marshall Urist Executive Vice President, Research & Investments | ◇ | — | — | — | — | — | — | ◇ |
George Lloyd Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments Departed during or after this year | ◇ | — | — | — | — | — | — | ◇ |
Terrance Coyne Executive Vice President & Chief Financial Officer | ◇ | — | — | — | — | — | — | ◇ |
Christopher Hite Executive Vice President & Vice Chairman | ◇ | — | — | — | — | — | — | ◇ |
Pablo Legorreta Chairman and Chief Executive Officer | ◇ | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Pablo Legorreta | RSU | ◇ | ◇ | — | — |
| George Lloyd | RSU | ◇ | ◇ | — | — |
| Terrance Coyne | RSU | ◇ | ◇ | — | — |
| Marshall Urist | RSU | ◇ | ◇ | — | — |
| Christopher Hite | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Vlad Coric, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Gregory Norden | ◇ | ◇ | — | — | — | — | ◇ |
Bonnie Bassler, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Errol De Souza, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Catherine Engelbert | ◇ | ◇ | — | — | — | — | ◇ |
David Hodgson | ◇ | ◇ | — | — | — | — | ◇ |
Ted Love, M.D Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Elizabeth Weatherman | ◇ | ◇ | — | — | — | — | ◇ |
Carole Ho, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Henry Fernandez | ◇ | ◇ | — | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- AbbVie ABBV
- Amgen AMGN
- Apollo APO
- Ares ARES
- Biogen BIIB
- BioMarin BMRN
- Blackstone BX
- Bristol-Myers Squibb BMY
- Carlyle CG
- Gilead GILD
- Incyte INCY
- Johnson & Johnson JNJ
- KKR KKR
- Merck & Co. MRK
- Pfizer PFE
- Regeneron REGN
- TPG TPG
- Vertex Pharmaceuticals VRTX
Biopharmaceutical Peer Group
- AbbVie ABBV
- Amgen AMGN
- Biogen BIIB
- BioMarin BMRN
- Bristol-Myers Squibb BMY
- Gilead GILD
- Incyte INCY
- Johnson&Johnson JNJ
- Merck & Co. MRK
- Pfizer PFE
- Regeneron REGN
- Vertex Pharmaceuticals VRTX
Capital Allocator Peer Group
- Apollo APO
- Ares ARES
- Blackstone BX
- Carlyle CG
- KKR KKR
- TPG TPG
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 12, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 6, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 22, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 23, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 24, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Pablo Legorreta (Chairman and Chief Executive Officer), FY2025 total compensation $937,500 (base salary $937,500) [exec_comp, SEC accession 0001140361-26-014239, filed 2026-04-10]What this page does not include
Everything above is a fact Royalty Pharma disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Royalty Pharma sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
112 figures on this page: 106 cited to the filing that reported them, 6 calculated from figures it prints.
106 cited to the filing
6 calculated from the filing
Documents cited
- 0001193125-26-257432Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001140361-26-014239CEO Pay Ratio · Director Compensation · Outstanding Equity Awards at 2025 Fiscal Year-End · Summary Compensation Table
- 0001193125-25-117771Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-24-156183Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001140361-24-022029Summary Compensation Table
- 0001193125-23-173169Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-22-180305Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-21-200603Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Royalty Pharma executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RPRX (accessed 2026).
Short form: data: Velarion
The Royalty Pharma brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Royalty Pharma and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Royalty Pharma discloses
The companies named in RPRX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}